Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNMBiotechnology
-$0.39 today
- Market cap
- $326.66M
- Beta
- 0.89
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$1.57
Volume 0.20M
Average 0.26M
CTNM EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Contineum Therapeutics, Inc. Class A Common StockNASDAQ: CTNM
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$14.37M, compared with -$15.91M a year earlier. Trailing-twelve-month EBITDA was -$58.12M.
Context
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$49.12M (+17.7%) for the fiscal year ending Dec 2026, a step up from the -42.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$14.37M+4.6% QoQ
- Last fiscal yearDec 2025
- -$59.66M-42.0% YoY
- LTMMar 2026
- -$58.12M-17.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +9.7% | — | — |
| 1 year | -42.0% | +17.7% | +59.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (59.66M) USD
- Year-over-year change
- -42.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (59.66M) | -42.0% |
| FY2024 | 2024-12-31 | (42M) | -278.2% |
| FY2023 | 2023-12-31 | 23.57M | +200.2% |
| FY2022 | 2022-12-31 | (23.54M) | +16.9% |
| FY2021 | 2021-12-31 | (28.34M) | — |
EBITDA vs competitors
How CTNM compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -17.3% is the 3rd highest of 7, against a peer median of -28.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$39.05M USD | — | — | — |
| LTM Mar 2026 | -$55.86M USD | -33.8% | — | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | -$58.12M USD | -17.3% | — | — |
| LTM Mar 2026 | -CHF 64.45M CHF | -29.6% | — | 1740.8% | |
| LTM Mar 2026 | -$71.29M USD | -16.9% | — | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$118.15M USD | -28.2% | — | 590.7% |
| LTM Mar 2026 | -$198.91M USD | -147.8% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$217.64M USD | +15.4% | — | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding CTNM) | — | -28.9% | — | 1165.8% | |
Competitors are the stored peer set for CTNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 50M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 258K | 0 |
| Gross Profit | 0 | 0 | 50M | (258K) | 0 |
| Gross Margin | — | — | 100.0% | — | — |
| Research & Development | 22.36M | 16.89M | 27.6M | 38.16M | 51.52M |
| Selling, General & Admin | 6.29M | 5.83M | 6.32M | 12.47M | 16.54M |
| Operating Expenses | 28.65M | 22.72M | 66.08M | 50.64M | 68.06M |
| Depreciation & Amortization | 325K | 329K | 195K | 258K | 323K |
| EBITDA | (28.34M) | (23.54M) | 23.57M | (42M) | (59.66M) |
| EBITDA Margin | — | — | 47.1% | — | — |
| Operating Income | (28.65M) | (22.72M) | (16.08M) | (50.89M) | (68.06M) |
| Operating Margin | — | — | -32.2% | — | — |
| Interest Income | 77K | 761K | 4.61M | 8.91M | 8.25M |
| Interest Expense | 332K | 388K | 208K | 0 | 0 |
| Other Income / Expenses | (354K) | (1.53M) | 39.25M | 8.64M | 8.08M |
| Income Before Tax | (29M) | (24.25M) | 23.17M | (42.26M) | (59.98M) |
| Pre-Tax Margin | — | — | 46.3% | — | — |
| Income Tax Expense | 0 | 0 | 450K | 0 | 0 |
| Net Income | (29M) | (24.25M) | 22.72M | (42.26M) | (59.98M) |
| Net Margin | — | — | 45.4% | — | — |
| EPS (Basic) | (1.15) | (0.97) | 0.13 | (1.63) | (2.17) |
| EPS (Diluted) | (1.15) | (0.97) | 0.13 | (1.63) | (2.17) |
| Weighted Avg Shares | 25.13M | 25.13M | 25.13M | 25.85M | 27.7M |
| Weighted Avg Shares (Diluted) | 25.13M | 25.13M | 25.13M | 25.85M | 27.7M |
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
Intrinsic Alpha fair value
Locked
Current Price
$9.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.